Workflow
Emergent BioSolutions(EBS)
icon
Search documents
SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 million
GlobeNewswire News Room· 2024-07-31 13:06
RSDL® is a medical device provided as a kit, with a lotion impregnated sponge in a packet, intended to remove or neutralize chemical warfare agents from the skin. RSDL removes or neutralizes chemical warfare agents (CWAs) including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas, and T-2 toxin. RSDL® is the only FDA-cleared device backed by 20 years of clinical data, that can remove or neutralize chemical warfare agents from the skin in one step. Over 15 million packets of RSDL® have been sold i ...
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
Newsfilter· 2024-07-31 12:53
"For years, our colleagues have proudly manufactured, sold and distributed RSDL® to many branches of the U.S. government to ensure military personnel safety and public health preparedness," said Joe Papa, president and chief executive officer at Emergent. "SERB is a well-positioned global leader that is expected to continue to make RSDL® readily available for the U.S. and allied governments." RSDL®is anFDA-cleared device provided as kit consisting of a lotion impregnated sponge in a packet, it is intended t ...
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
GlobeNewswire News Room· 2024-07-31 12:53
This transaction follows Emergent's announcement to sell its drug product facility in Baltimore-Camden, as well as operational changes, which are key actions in its multi-year plan. The net proceeds from the sale of RSDL® and the Baltimore-Camden facility will reduce or eliminate the Junior Capital Raise requirements under Emergent's amended credit facility, a requirement that was recently extended to September 29, 2024. At Emergent, our mission is to protect and enhance life. For 25 years, we've been at wo ...
Emergent BioSolutions Launches Opioid Emergency Preparedness 'Lay, Spray, Stay' Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
Newsfilter· 2024-07-24 11:30
Naloxone, the active ingredient in NARCAN® Nasal Spray, is a medication designed to rapidly reverses the effects of an opioid poisoning and is the standard of care for opioid overdose reversal. It is available over the counter and can be accessed at leading pharmacies and grocery stores nationwide, as well as online retailers. Emergent partnered with SAFE Project – an organization founded by Sandy Winnefeld, the former Chairman of the Joint Chiefs of Staff, and his wife, Mary – when they lost their son to a ...
Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in Canada
Newsfilter· 2024-07-22 12:00
Naloxone, the active ingredient in NARCAN® Nasal Spray, is a life-saving medication that can reverse an overdose from prescription and illicit opioids, such as heroin and fentanyl, when given in time. As an emergency public health measure, Health Canada first approved NARCAN® Nasal Spray in October 2016.i,ii In 2023, Emergent distributed approximately 22 million doses (~11 million two-dose cartons) in Canada and the U.S. through public interest organizations, such as community-based organizations, harm redu ...
Watch These 4 Overbought Stocks As Market Rotation Continues
MarketBeat· 2024-07-18 11:11
While the overall market has enjoyed an impressive 17% year-to-date gain, recent rotations and sector-specific outflows have created a ripe environment for potential pullbacks. The semiconductor sector, for example, has seen a notable decline, with the SMH ETF down nearly 10% from its 52-week highs. Significant market rotations can often lead to overbought stocks pulling back as capital shifts from overvalued sectors to undervalued opportunities. For example, the IWM ETF, which represents small caps, has su ...
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
Newsfilter· 2024-07-09 11:30
GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving its financial health, marked by robust cash generation and meaningful debt repayment. As set forth in its operational plan to transform the company over the next several years, Emergent is diligently executing its strategy to enhance operational efficiency, streamline costs, and generate cash to increase profitability and reduce the company's overall debt. Thi ...
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
GlobeNewswire News Room· 2024-07-09 11:30
GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving its financial health, marked by robust cash generation and meaningful debt repayment. As set forth in its operational plan to transform the company over the next several years, Emergent is diligently executing its strategy to enhance operational efficiency, streamline costs, and generate cash to increase profitability and reduce the company's overall debt. Thi ...
Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?
Benzinga· 2024-07-02 16:53
Loading... Loading... Nvidia Corp NVDA is trading lower Tuesday amid reports that the company faces antitrust charges from French regulators. These charges follow dawn raids conducted last September, which resulted in formal objections and a charge sheet against Nvidia. Meanwhile, on a positive note, Nvidia supplier Taiwan Semiconductor Manufacturing Co TSM plans to significantly boost its capital expenditures in 2025 due to high demand and progress in its 2nm technology. Industry reports indicate TSMC's ca ...
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
Newsfilter· 2024-07-02 12:13
The four awards include: "Securing multiple contract modifications with the U.S. government for our medical countermeasure products affirms that Emergent is a trusted biodefense partner, and also demonstrates the strength and sustainment of our product portfolio," said Paul Williams, senior vice president, products head at Emergent. "As part of our longstanding public-private partnership, we stand ready to continue fulfilling preparedness priorities and stockpiling efforts in the U.S. and abroad." Indicatio ...